Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ICPT
  • CUSIP: 45845P10
  • Web:
  • Market Cap: $2.83 billion
  • Outstanding Shares: 25,009,000
Average Prices:
  • 50 Day Moving Avg: $112.40
  • 200 Day Moving Avg: $112.97
  • 52 Week Range: $96.63 - $177.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.45
  • P/E Growth: -1.11
Sales & Book Value:
  • Annual Revenue: $45.55 million
  • Price / Sales: 62.04
  • Book Value: $9.60 per share
  • Price / Book: 11.77
  • EBIDTA: ($355,150,000.00)
  • Net Margins: -3,287.95%
  • Return on Equity: -66.97%
  • Return on Assets: -48.90%
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 14.57%
  • Quick Ratio: 14.57%
  • Average Volume: 372,074 shs.
  • Beta: -2.14
  • Short Ratio: 11.51

Frequently Asked Questions for Intercept Pharmaceuticals (NASDAQ:ICPT)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($3.61) EPS for the quarter, topping analysts' consensus estimates of ($4.27) by $0.66. The firm had revenue of $21 million for the quarter, compared to analyst estimates of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The company's revenue was up 4566.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($5.17) EPS. View Intercept Pharmaceuticals' Earnings History.

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?

17 equities research analysts have issued 1-year target prices for Intercept Pharmaceuticals' shares. Their predictions range from $60.00 to $350.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $193.31 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Intercept’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and beat on revenues. Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry so far in 2017." (5/8/2017)
  • 2. Cowen and Company analysts commented, "We attended EASL 2017 this past weekend where key latebreaker presentations." (4/24/2017)
  • 3. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
  • 4. Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)
  • 5. Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who owns Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (5.12%), State Street Corp (3.24%), BB Biotech AG (1.03%), First Trust Advisors LP (0.99%) and Macquarie Group Ltd. (0.97%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, David Shapiro, Klaus R Dr Veitinger, Lisa Bright, Luciano Adorini, Mark Pruzanski, Nicole Williams and Rachel Mcminn. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Marshall Wace LLP, First Trust Advisors LP, ING Groep NV, KCG Holdings Inc., State of Wisconsin Investment Board, ProShare Advisors LLC and AXA. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, David Shapiro, Lisa Bright, Mark Pruzanski and Rachel Mcminn. View Insider Buying and Selling for Intercept Pharmaceuticals.

Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Macquarie Group Ltd., Vanguard Group Inc., State Street Corp, Point72 Asset Management L.P., Geode Capital Management LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intercept Pharmaceuticals stock cost?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $112.99.

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 2 Sell Ratings, 5 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.47)
Consensus Price Target: $193.31 (71.09% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Credit Suisse Group AGBoost Price TargetOutperform$198.00 -> $201.00N/AView Rating Details
5/5/2017BMO Capital MarketsReiterated RatingOutperform$221.00 -> $223.00LowView Rating Details
5/5/2017LaidlawUpgradeSell -> Hold$115.00LowView Rating Details
5/4/2017Cantor FitzgeraldSet Price TargetSell$60.00LowView Rating Details
5/4/2017Oppenheimer Holdings Inc.Set Price TargetBuy$200.00LowView Rating Details
4/24/2017Cowen and CompanyReiterated RatingBuy$225.00HighView Rating Details
3/17/2017WedbushReiterated RatingOutperform$224.00LowView Rating Details
2/28/2017Citigroup IncSet Price TargetBuy$275.00 -> $240.00N/AView Rating Details
2/24/2017Leerink SwannLower Price TargetMarket Perform$116.00 -> $110.00N/AView Rating Details
2/23/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/16/2017Robert W. BairdReiterated RatingOutperform$332.00N/AView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
9/28/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
8/5/2016Morgan StanleyReiterated RatingSell$80.00N/AView Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
5/31/2016Goldman Sachs Group IncBoost Price TargetNeutral$114.00 -> $128.00N/AView Rating Details
4/9/2016Bank of America CorpReiterated RatingSell$144.00N/AView Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91N/AView Rating Details
8/7/2015Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
7/24/2015Royal Bank of CanadaReiterated RatingOutperform$490.00N/AView Rating Details
7/1/2015MLV & Co.Reiterated RatingHoldN/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings History by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
2017 EPS Consensus Estimate: ($14.95)
2018 EPS Consensus Estimate: ($12.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($4.62)($3.39)($4.02)
Q2 20174($4.08)($3.69)($3.86)
Q3 20174($4.01)($2.91)($3.60)
Q4 20173($3.85)($2.88)($3.47)
Q1 20181($3.61)($3.61)($3.61)
Q2 20181($3.30)($3.30)($3.30)
Q3 20181($2.87)($2.87)($2.87)
Q4 20181($2.32)($2.32)($2.32)
(Data provided by Zacks Investment Research)


Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 82.28%
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.62View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.00View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.06View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.68View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.58View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.00View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.00View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.92View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.64View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.65View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.96View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.72View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.50View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.40View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.78View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intercept Pharmaceuticals (NASDAQ:ICPT)
Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateHeadline logoIntercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid) - May 19 at 10:21 AM logoIntercept Pharmaceuticals Inc (ICPT) Insider Sells $13,530.62 in Stock - May 18 at 10:44 PM logoIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : May 18, 2017 - May 18 at 9:29 AM logoFBR & Co Comments on Intercept Pharmaceuticals Inc's Q2 2017 Earnings (ICPT) - May 18 at 8:06 AM logoIntercept to Present at Upcoming Conferences - May 17 at 5:47 PM logoETFs with exposure to Intercept Pharmaceuticals, Inc. : May 15, 2017 - May 15 at 5:20 PM logoIntercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 6:32 PM logoCantor Fitzgerald Equities Analysts Raise Earnings Estimates for Intercept Pharmaceuticals Inc (ICPT) - May 12 at 12:52 PM logoInsider Selling: Intercept Pharmaceuticals Inc (ICPT) Insider Sells 426 Shares of Stock - May 11 at 12:06 AM logoIntercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : May 8, 2017 - May 9 at 12:30 PM logoIntercept Pharmaceuticals Inc (ICPT) Announces Earnings Results - May 9 at 12:16 AM logoIntercept Pharmaceuticals Inc (ICPT) Posts Earnings Results, Beats Estimates By $0.66 EPS - May 8 at 11:53 PM logoIntercept Pharmaceuticals Inc (ICPT) Announces Earnings Results, Beats Expectations By $0.66 EPS - May 8 at 10:26 PM logoIntercept Pharmaceuticals Inc (ICPT) Raised to "Hold" at Zacks Investment Research - May 8 at 3:34 PM logoOppenheimer Holdings Research Analysts Reduce Earnings Estimates for Intercept Pharmaceuticals Inc (ICPT) - May 8 at 12:26 PM logoQ2 2017 EPS Estimates for Intercept Pharmaceuticals Inc Increased by Wedbush (ICPT) - May 8 at 8:21 AM logoIntercept Pharmaceuticals Inc (ICPT) Given a $200.00 Price Target at Oppenheimer Holdings Inc. - May 7 at 8:02 AM logoIntercept Pharmaceuticals Inc (ICPT) PT Set at $60.00 by Cantor Fitzgerald - May 7 at 7:40 AM logoEdited Transcript of ICPT earnings conference call or presentation 4-May-17 12:30pm GMT - May 6 at 5:53 PM logoIntercept Pharmaceuticals Inc (ICPT) Receives Average Recommendation of "Hold" from Brokerages - May 6 at 12:35 AM logoSomewhat Favorable Press Coverage Very Likely to Impact Intercept Pharmaceuticals (ICPT) Share Price - May 6 at 12:33 AM logoFY2021 Earnings Forecast for Intercept Pharmaceuticals Inc Issued By Wedbush (ICPT) - May 5 at 8:24 PM logoIntercept Pharmaceuticals' (ICPT) "Outperform" Rating Reaffirmed at Credit Suisse Group AG - May 5 at 8:20 PM logoIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : May 5, 2017 - May 5 at 5:48 PM logoIntercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat - May 5 at 5:48 PM logoIntercept Pharmaceuticals Inc (ICPT) Earns "Outperform" Rating from BMO Capital Markets - May 5 at 5:01 PM logoIntercept Pharmaceuticals Inc (ICPT) Raised to "Hold" at Laidlaw - May 5 at 10:30 AM logoIntercept Pharmaceuticals (ICPT) Q1 2017 Results - Earnings Call Transcript - May 5 at 4:01 AM logoIntercept (ICPT) Reports A Narrower Loss in Q1 - Yahoo Finance - May 4 at 11:38 AM logoIntercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update - May 4 at 11:38 AM logoIntercept reports 1Q loss - May 4 at 11:38 AM logoIntercept (ICPT) Reports A Narrower Loss in Q1 - May 4 at 11:38 AM logoDavid Shapiro Sells 1,117 Shares of Intercept Pharmaceuticals Inc (ICPT) Stock - May 4 at 1:29 AM logoIntercept Pharmaceuticals Inc (ICPT) Insider Rachel Mcminn Sells 114 Shares - May 4 at 1:27 AM logoIntercept Pharmaceuticals (ICPT) Given Coverage Optimism Score of 0.16 - May 2 at 10:30 PM logoZacks Investment Research Downgrades Intercept Pharmaceuticals Inc (ICPT) to Sell - May 1 at 11:20 PM logoIntercept Pharmaceuticals (ICPT) Given Coverage Optimism Score of 0.39 - April 29 at 9:14 PM logo$15.92 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter - April 29 at 10:30 AM logoIs Intercept (ICPT) Poised for a Beat This Earnings Season? - Nasdaq - April 28 at 11:48 PM logoIntercept to Report First Quarter 2017 Financial Results on May 4 and Present at Upcoming Conference - April 27 at 5:45 PM logoIntercept Pharmaceuticals Inc (ICPT) Expected to Post Earnings of -$4.27 Per Share - April 27 at 9:56 AM logoIntercept Pharmaceuticals (ICPT) Earns Media Impact Score of 0.12 - April 27 at 12:00 AM logoIntercept Pharmaceuticals' (ICPT) Buy Rating Reiterated at Cowen and Company - April 24 at 11:20 PM logoCelgene (CELG) to Post Q1 Earnings: What's in the Cards? - April 24 at 5:30 PM logoIntercept Pharmaceuticals (ICPT) Given Daily News Sentiment Score of -0.12 - April 23 at 3:13 PM logoIntercept Pharma (ICPT) to Present New Ocaliva® (obeticholic acid) & INT-767 Data at EASL 2017 - - April 21 at 10:47 PM logoIntercept Pharmaceuticals Inc to Post FY2019 Earnings of ($16.18) Per Share, Leerink Swann Forecasts (ICPT) - April 21 at 5:35 PM logoAlexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise? - April 21 at 10:46 AM logoIntercept Pharma (ICPT) to Present New Ocaliva® (obeticholic acid) & INT-767 Data at EASL 2017 - April 19 at 10:45 PM logoIntercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017 - April 19 at 11:28 AM



Intercept Pharmaceuticals (ICPT) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff